Tamoxifen Citrate
54965-24-1CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1.O=C(O)CC(O)(CC(=O)O)C(=O)OFQZYTYWMLGAPFJ-OQKDUQJOSA-NTamoxifen Citrate can cause developmental toxicity according to state or federal government labeling requirements.
54965-24-1FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
安全信息仅供参考,不能替代供应商安全技术说明书(SDS)、适用法规与专业评估。
Danger
H302 (97.4%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P263, P264, P270, P273, P280, P301+P317, P318, P330, P391, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 78 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Hazard Traits - Developmental Toxicity
Tamoxifen citrate: Does not have an individual approval but may be used under an appropriate group standard
Drug Induced Liver Injury Rank (DILIrank 2.0)
Tamoxifen citrate
vMost-DILI-concern
8
Warnings & precautions
DOI:10.1016/j.drudis.2016.02.015
TAMOXIFEN CITRATE
Selective Estrogen Receptor Modulators [MoA]; Estrogen Agonist/Antagonist [EPC]
Compounds which inhibit or antagonize the action or biosynthesis of estrogenic compounds.
Antineoplastic agents that are used to treat hormone-sensitive tumors. Hormone-sensitive tumors may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumor regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumors may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukemias. (From AMA Drug Evaluations Annual 1994, p2079)
A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
概述枸橼酸他莫昔芬 (三苯氧胺,tamoxifen citrat e,简称 TCT ),是一种雌激素(estrogen)竞争性拮抗剂,为非固醇类抗雌激素药物,在体内能与雌激素(雌二醇) 竞争,与乳癌细胞雌激素受体相 结合,从而抑制雌激素对癌细胞的作用,使肿瘤细胞生长发育受阻,而发挥抗癌效果。临床上常用于治疗各类乳腺癌,尤其适用于雌激素受体和孕酮受体阳性以及前列腺特异性抗原水平较低的绝经后乳腺癌妇女患者。
用途途用于治疗晚期、复发性乳腺癌和卵巢癌等病症
DTXSID8021301CHEMBL786